Pierluigi Paracchi

CEO and CO-Founder Genenta Science
“Not a lot of people are aware that the first ever ex-vivo gene therapy has been approved not in Boston or in Silicon Valley but in Milano thanks to the collaboration between San Raffaele Hospital and a big pharma company. In Italy we are at the frontier of the advanced therapies. Genenta (Nasdaq: GNTA) is now developing the second generation of cell&gene therapies, moving from rare diseases to oncology, and leveraging experience and track record of the Italian leadership in this space.”

Dicover Other Speakers